The hemostatic system and angiogenesis in malignancy

Neoplasia

Volumn 3, Issue 5, 2001, Pages 371-384

  Wojtukiewicz, Marek Z ^a   Sierko, Ewa ^a   Klement, Petr ^b,c   Rak, Janusz ^c,d  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^c MCMASTER UNIVERSITY   (Canada)

^d HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; FIBRIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; THROMBIN; THROMBOPLASTIN;

ANGIOGENESIS; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CANCER; DISEASE ASSOCIATION; FIBRINOLYSIS; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; THROMBOCYTE;

EID: 0034770081     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900184     Document Type: Article

References (255)

1. Hemostatic alterations in cancer patients
2. Coagulation abnormalities in malignancy
3. The prethrombotic state in cancer
4. Hemostasis and cancer
5. Cancer and thrombosis
6. Abnormalities of hemostasis in malignant disease
7. Tissue factor in cancer angiogenesis and metastasis
8. Mechanism of the coagulopathy associated with acute promyelocytic leukemia - Clinical conference
9. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung
10. Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ
11. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary
12. Expression of prothrombin fragment 1 + 2 in cancer tissue as an indicator of local activation of blood coagulation
13. Tumors: Wounds that do not heal
14. Molecular framework for angiogenesis: A complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines
15. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells
16. Tumor angiogenesis: Therapeutic implications
17. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
18. Angiogenesis in cancer and other diseases
19. Mechanisms of angiogenesis and arteriogenesis
20. Reciprocal paracrine interactions between tumor cells and endothelial cells. The "angiogenesis progression" hypothesis
21. Angiogenesis-dependent tumor spread in reinforced fibrin clot culture
22. Anti-integrin αbβ3 blocks human breast cancer growth and angiogenesis in human skin
23. Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression
24. Direct in vitro lysis of metastatic tumor cells by cytoline-activated murine vascular endothelial cells
25. Halting angiogenesis suppresses carcinoma cell invasion
26. A paracrine migration-stimulating factor for metastatic tumor cells secreted by mouse hepatic sinusoidal endothelial cells: Identification as complement component C3b
27. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
28. What is the evidence that tumors are angiogenesis-dependent?
29. Molecular mechanism of developmental and tumor angiogenesis
30. Angiogenesis in cancer, vascular, rheumatoid and other disease
31. How tumors become angiogenic
32. Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression
33. Tumor induction of VEGF promoter activity in stromal cells
34. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis
35. Activated macrophages induce vascular proliferation
36. Mechanisms of angiogenesis in the brain
37. Vascular endothelial growth factor: Molecular and biological aspects
38. Involvement of platelets in tumour angiogenesis?
39. The hemostatic system as a regulator of angiogenesis
40. Oncogenes and angiogenesis: Signaling three-dimensional tumor growth
41. Endothelial cell proliferation as a novel approach to targeting tumor therapy
42. Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy
43. Antiangiogenic domains shared by thrombospondins and metallospondins, a new family of angiogenic inhibitors
44. Pigment epithelium - Derived factor: A potent inhibitor of angiogenesis
45. Both tumor necrosis factor receptors, TNFR60 and TNFR80, are involved in signaling endothelial tissue factor expression by juxtacrine tumor necrosis factor alpha
46. Maspin is an angiogenesis inhibitor
47. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
48. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin
49. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
50. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth
51. Oncogenes as inducers of tumor angiogenesis
52. Oncogenes and tumor angiogenesis: Differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts
53. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression
54. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein
55. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas
56. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression
57. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras - Transformed cells through a hypoxia inducible factor-1 transcriptional element
58. Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor
59. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways
60. Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by cell density
61. Neutralizing antibodies against EGF and ErbB-2/neu receptor tyrosine kinases down-regulate VEGF production by tumor ceils in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
62. Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer
63. Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression
64. Tumor angiogenesis factor
65. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
66. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
67. The biology of vascular endothelial growth factor
68. Vascular permeability factor/vascular endothelial growth factor: A multifunctional angiogenic cytokine
69. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression
70. Impact of oncogenes on tumor angiogenesis: Mutant K-ras upregulation of VEGF/VPF is necessary but not sufficient for tumorigenicity of human colorectal carcinoma cells
71. Vascular endothelial growth factor (VEGF) and its receptors
72. VEGFs, receptors and angiogenesis
73. Vascular-specific growth factors and blood vessel formation
74. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke
75. Src kinase regulation of VEGF signaling and vascular permeability following cerebral ischemia
76. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis
77. Factor XIIIa supports microvascular endothelial cell adhesion and inhibits capillary tube formation in fibrin
78. Cancer cell procoagulants and their role in malignant disease
79. Tissue factor as a tumor procoagulant
80. Immunohistochemical identification of tissue factor in solid tumors
81. Heterogenous expression of endothelial cell associated proteins in gliomas of different malignancy
82. Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression
83. Expression of tissue factor and tissue factor pathway inhibitor in situ in laryngeal carcinoma
84. Tissue factor expression and angiogenesis in human prostate carcinoma
85. Pathways of coagulation/fibrinolysis activation in malignancy
86. Tissue factor controls the balance of angiogenic and antianglogenic properties of tumor cells in mice
87. In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease
88. Tumor angiogenesis and tissue factor
89. Molecular mechanisms linking thrombosis and angiogenesis in cancer
90. Pentoxifylline inhibits hypoxia-induced upregulation of tumor cell tissue factor and vascular endothelial growth factor
91. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor
92. Tissue factor - Dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII
93. Role of tissue factor in embryonic blood vessel development
94. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation
95. Activation of coagulation and angiogenesis in cancer: Immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer
96. Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia
97. Protein kinase C-beta and oxygen deprivation. A novel Egr-1 - Dependent pathway for fibrin deposition in hypoxemic vasculature
98. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
99. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo
100. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin
101. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia
102. Identification of hypoxically inducible mRNAs in HeLa cells using differential display PCR. Role of hypoxia-inducible factor-1
103. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1
104. Regulation of tissue factor gene expression in human monocytic and endothelial cells
105. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system
106. Mouse embryogenesis requires the tissue factor extracellular domain but not the cytoplasmic domain
107. The cytoplasmic domain of tissue factor is phosphorylated by a protein kinase C - Dependent mechanism
108. 2+ signals in J82 cells, transfected COS-1 cells, Madin-Darby canine kidney cells and in human endothelial cells induced to synthesize tissue factor
109. 2+ oscillations in Madin-Darby canine kidney cells only when proteolytically active
110. Binding of factor VIIa to tissue factor on keratinocytes induces gene expression
111. Tissue factor- and factor X - Dependent activation of protease-activated receptor 2 by factor VIIa
112. Cellular consequences of the initiation of blood coagulation
113. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts
114. Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor
115. Factor VIIa - Induced p44/42 mitogen-activated protein kinase activation requires the proteolytic activity of factor VIIa and is independent of the tissue factor cytoplasmic domain
116. Factor VIIa/tissue factor - Induced signaling via activation of Src-like kinases, phosphatidylinositol 3-kinase, and Rac
117. Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa
118. Tissue factor pathway inhibitor
119. Ligand-induced protease receptor translocation into caveolae: A mechanism for regulating cell surface proteolysis of the tissue factor - Dependent coagulation pathway
120. Diverse functions of protease receptor tissue factor in inflammation and metastasis
121. Tissue factor signaling
122. Specificity, diversity, and convergence in VEGF and TNF-{alpha} signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells
123. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells
124. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells
125. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
126. Fibrinogen - Fibrin transformation in situ in renal cell carcinoma
127. Fibrinogen - Fibrin conversion in laryngeal cancer in situ: A tissue factor dependent process
128. Immunohistochemical demonstration of fibrin II in gastric cancer tissue
129. Cellular localization of enzymatically active thrombin in intact human tissues by hirudin binding
130. Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface
131. Solid tumor cells express functional "tethered ligand" thrombin receptor
132. Anticoagulants as cancer therapy
133. The haemostatic balance - Astrup revisited
134. Prothrombin and its derivatives stimulate motility of melanoma cells
135. Thrombin increases the metastatic potential of tumor cells
136. Tissue factor - Initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells
137. Thrombin-induced increase in endothelial permeability is associated with changes in cell-to-cell junction organization
138. Time course of recovery of endothelial cell surface thrombin receptor (PAR-1) expression
139. Effects of thrombin/thrombosis in angiogenesis and tumour progression
140. On the mechanism(s) of thrombin-induced angiogenesis
141. On the mechanism of thrombin-induced angiogenesis. Potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors
142. Thrombin promotes angiogenesis by a mechanism independent of fibrin formation
143. The role of thrombin in tumor cell metastasis
144. SHP2 association with VE-cadherin complexes in human endothelial cells is regulated by thrombin
145. Thrombin promotes endothelial cell alignment in Matrigel in vitro and angiogenesis in vivo
146. Organ-derived microvessel endothelial cells exhibit differential responsiveness to thrombin and other growth factors
147. Thrombin induces endothelial cell growth via both a proteolytic and a non-proteolytic pathway
148. 2+, prostacyclin, or permeability
149. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets
150. Thrombin-induced release of active basic fibroblast growth factor - Heparan sulfate complexes from subendothelial extracellular matrix
151. Specificity of the thrombin-induced release of tissue plasminogen activator from cultured human endothelial cells
152. Thrombin induces the activation of progelatinase A in vascular endothelial cells. Physiologic regulation of angiogenesis
153. Tumor suppressor gene control of angiogenesis
154. Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor - Stimulated capillary endothelial cells
155. Human prothrombin fragment 1 and 2 inhibit bFGF-induced BCE cell growth
156. Fibrinopeptide A (FPA) level and fibrinogen kinetics in patients with malignant disease
157. Review: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
158. Fibrin regulation of interleukin-8 gene expression in human vascular endothelial cells
159. Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells
160. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
161. Alternative adhesion sites in human fibrinogen for vascular endothelial cells
162. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation
163. Fibrinogen and fibrin protect fibroblast growth factor-2 from proteolytic degradation
164. Potentiation of endothelial cell proliferation by fibrin(ogen)-bound fibroblast growth factor-2
165. Binding of basic fibroblast growth factor to fibrinogen and fibrin
166. Fibrin induction of tissue factor expression in human vascular endothelial cells
167. Angiogenic activity of fibrin degradation products is located in fibrin fragment E
168. Cell proliferation on fibrin: Modulation by fibrinopeptide cleavage
169. Endothelial cell spreading on fibrin requires fibrinopeptide B cleavage and amino acid residues 15-42 of the beta chain
170. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
171. Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma
172. Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization
173. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma
174. Inhibition of prostate cancer neovascularization and growth by urokinase - Plasminogen activator receptor blockade
175. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc
176. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer
177. Immunohistochemical localisation of tissue plasminogen activator in human brain tumours
178. Transcriptional and posttranscriptional regulation of urokinase-type plasminogen activator expression in endothelial cells by basic fibroblast growth factor
179. Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor
180. Biological roles of fibroblast growth factor-2
181. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro
182. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo
183. Regulation of vascular endothelial growth factor receptor-2 (FIk-1) expression in vascular endothelial cells
184. VEGF and tPA co-expressed in malignant glioma
185. Expression of the proteolytic factors, tPA and uPA, PAI-1 and VEGF during malignant glioma progression
186. Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers
187. Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors
188. Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices
189. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA - u-PAR - PAI-1 system
190. In vivo paracrine interaction between urokinase and its receptor: Effect on tumor cell invasion
191. The role of the pericellular fibrinolytic system in angiogenesis
192. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins
193. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure
194. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor - Mediated cell adhesion and release?
195. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor
196. Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits anglogenesis: Partial activity within domain 5
197. Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia
198. Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle
199. The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway
200. Can knockout mice help dissect relevant genes in hypertension? Evidence and confounding factors
201. Mechanisms of signaling through urokinase receptor and the cellular response
202. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor
203. Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: A self-regulating system
204. Hepatocyte growth factor/scatter factor (HGF/SF) induces vascular permeability factor expression by cultured keratinocytes
205. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1)
206. Transforming growth factor-beta: Vasculogenesis, angiogenesis, and vessel wall integrity
207. An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes
208. Vascular endothelial growth factor is induced in response to transforming growth factor beta in fibroblastic and epithelial cells
209. Transforming growth factor-beta 1 inhibits generation of angiostatin by human pancreatic cancer cells
210. Angiostatin induces canal sustains dormancy of human tumors in mice
211. Therapeutic potentials of angiostatin in the treatment of cancer
212. Angiostatin 4,5: A naturally occurring human angiogenesis inhibitor
213. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis
214. Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3
215. Angiostatin and endostatin: Endogenous inhibitors of tumor growth
216. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice
217. Combined effects of angiostatin and ionizing radiation in antitumour therapy
218. Angiostatin binds ATP synthase on the surface of human endothelial cells
219. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation
220. Endostatin stimulates tPA mediated plasmin formation. Meeting Proceedings 2000, Keystone Symposium
221. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology
222. Cancer procoagulant stimulates platelet adhesion
223. Vascular endothelial growth factor - Stimulated endothelial cells promote adhesion and activation of platelets
224. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation
225. Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells
226. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures
227. Human platelet - Derived mitogens: II. Subcellular localization of insulin-like growth factor I to the alpha-granule and release in response to thrombin
228. Human platelet - Derived mitogens: I. Identification of insulin-like growth factors I and II by purification and N alpha amino acid sequence analysis
229. Megakaryocyte synthesis is the source of epidermal growth factor in human platelets
230. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy
231. Evidence that platelets promote tube formation by endothelial cells on matrigel
232. Autocrinological role of basic fibroblast growth factor on tube formation of vascular endothelial cells in vitro
233. Clinical implications of tumor-associated neovascularization and current antiangiogenic strategies for the treatment of malignancies of pancreas
234. 165 using several concurrent mechanisms
235. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization
236. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity
237. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4
238. Inhibition of in vitro angiogenesis by platelet factor-4 - Derived peptides and mechanism of action
239. Viral vector - Mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth
240. Thrombospondin as an inhibitor of angiogenesis
241. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1
242. Thrombospondin-1 is a major activator of TGF-beta 1 in vivo
243. HGF/SF in angiogenesis
244. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor
245. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40
246. Thrombin signalling and protease-activated receptors
247. Activation of thrombin activatable fibrinolysis inhibitor (TAFI) by uPAR may cause thrombotic complications in cancer
248. Thymidine phosphorylase is angiogenic and promotes tumor growth
249. Thrombin induces the release of angiopoietin-1 from platelets
250. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor
251. Hepatocyte growth factor (HGF)/NK1 is a naturally occurring HGF/scatter factor variant with partial agonist/antagonist activity
252. Identification of a competitive HGF antagonist encoded by an alternative transcript
253. A tumor suppressor - Dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin
254. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas